|
Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH)
RECRUITINGN/ASponsored by Isala
Actively Recruiting
PhaseN/A
SponsorIsala
Started2024-03-26
Est. completion2027-08-30
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06342843
Summary
This study will compare postoperative pain, health related quality of life (HRQoL), function, rehabilitation, urinary incontinence, muscle atrophy and component positioning in total hip arthroplasty (THA) using the posterolateral approach (PLA) or the direct superior approach (DSA). In addition, the CT images will be used to validate a new metal artefact reduction technique.
Eligibility
Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria: Subject * Has symptomatic incapacitating coxarthrosis in whom total hip arthroplasty (THA) is indicated, diagnosed by both physical examination and pelvic/hip X-ray * Has signed informed consent * Is ageing 18 years or older at time of study entry * Is competent and able to participate in follow-up Exclusion Criteria: * Previous ipsilateral hip surgery * BMI \>35 kg/m2 * Contralateral incapacitating coxarthrosis, diagnosed by both physical examination and pelvic/hip X-ray * Neurological conditions influencing walking pattern * Inability to walk without walking aid preoperatively * Rheumatoid arthritis (RA) * Severe hip dysplasia * Cognitive impairment * Malignancies or metastases involving the hip joint or the nearby soft tissues * Inability to speak and write Dutch language
Conditions2
ArthritisOsteoarthritis, Hip
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorIsala
Started2024-03-26
Est. completion2027-08-30
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06342843